Bredefeld Cindy L, Choi Paula, Cullen Tiffany, Nicolich-Henkin Sophie J, Waters Lauren
Department of Medicine, New York University Grossman Long Island School of Medicine, NYU Langone Hospital-Long Island, Garden City, NY, 11530, USA.
Department of Foundations of Medicine, New York University Grossman Long Island School of Medicine, NYU Langone Hospital-Long Island, Mineola, NY, 11501, USA.
Curr Atheroscler Rep. 2024 Dec 19;27(1):18. doi: 10.1007/s11883-024-01266-8.
Atherosclerotic cardiovascular disease (ASCVD) and diabetes are leading causes of morbidity and mortality in the United States and globally. Statin medications, a cornerstone of ASCVD prevention and treatment strategies, have been demonstrated to cause hyperglycemia and new onset diabetes mellitus (NODM). The purpose of this review is to summarize existing and emerging knowledge around the intersection of statins and these two important clinical problems.
Since initial reporting of statin-induced hyperglycemia and NODM, the totality of available data corroborates an association between incident diabetes and statin use. A consensus that high-intensity statin and individuals with obesity or glycemic parameters approximating diabetes thresholds constitute the majority of risk exists. Alterations in insulin signaling, glucose transport and gastrointestinal microbiota are leading hypotheses underlying the mechanisms of statin-induced hyperglycemia. The probability of NODM based on an individual's risk factors and statin specific properties can be anticipated. This risk needs to be contextualized with the risk of ASCVD. In order to effectively adjudicate the risk of NODM, improvement in formulating and ultimately conveying a comprehensive ASCVD risk assessment to patients is necessary.
动脉粥样硬化性心血管疾病(ASCVD)和糖尿病是美国乃至全球发病和死亡的主要原因。他汀类药物是ASCVD预防和治疗策略的基石,但已证实其可导致高血糖和新发糖尿病(NODM)。本综述旨在总结关于他汀类药物与这两个重要临床问题交叉领域的现有及新出现的知识。
自从首次报道他汀类药物引起的高血糖和NODM以来,现有全部数据均证实糖尿病发病与他汀类药物使用之间存在关联。已形成一种共识,即高强度他汀类药物以及肥胖个体或血糖参数接近糖尿病阈值的个体构成了主要风险人群。胰岛素信号传导、葡萄糖转运和胃肠道微生物群的改变是他汀类药物引起高血糖机制的主要假说。基于个体风险因素和他汀类药物特定属性,可以预测发生NODM的可能性。这种风险需要结合ASCVD的风险来考量。为了有效判定NODM的风险,有必要改进向患者制定并最终传达全面的ASCVD风险评估。